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Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) activates NF-jB signaling pathways
through the two C-terminal regions, CTAR1 and CTAR2. BS69 has previously been shown to be
involved in LMP1-induced c-Jun N-terminal kinase activation through CTAR2 by interacting with
tumor necrosis factor (TNFR) receptor-associated factor 6. In the present study, our manipulation
of BS69 expression clearly indicates that BS69 negatively regulates LMP1-mediated NF-jB activation
and up-regulates IL-6 mRNA expression and IjB degradation. Our immunoprecipitation experi-
ments suggest that BS69 decreases complex formation between LMP1 and TNFR-associated death
domain protein (TRADD).
Structured summary:
MINT-7032462: LMP1 (uniprotkb:P03230) physically interacts (MI:0218) with TRADD (uniprotkb:Q15628)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7032451: BS69 (uniprotkb:Q15326) and LMP1 (uniprotkb:P03230) colocalize (MI:0403) by ﬂuores-
cence microscopy (MI:0416)
MINT-7032478: LMP1 (uniprotkb:P03230) physically interacts (MI:0218) with BRAM1 (uniprotkb:Q15326)
by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Epstein–Barr virus (EBV) is linked to the development of mul-
tiple malignancies, including post-transplant lymphoma, Hodgkin
disease, and nasopharyngeal carcinoma. EBV-encoded latent
membrane protein 1 (LMP1) is expressed in many EBV-associated
tumor cells and is responsible for most of the altered cellular
growth properties. Structurally, LMP1 is an integral membrane
protein of 386 amino acids (aa) that consists of a short cytoplas-
mic N-terminal domain (aa 1–24), six transmembrane domains
(aa 25–186) and a long cytoplasmic C-terminal tail (aa
187–386) [1–3]. The cytoplasmic C-terminal tail contains two C-
terminal activation regions (CTARs), CTAR1 and CTAR2, which
are required for LMP1-transduced signaling through tumor necro-
sis factor receptor (TNFR)-associated factors (TRAFs) [1,4]. CTAR1
contains a consensus TRAF-binding motif (PXQXT), and can bindchemical Societies. Published by E
. Matsuda).to TRAFs 1, 2, 3 and 5 [1,5–8]. CTAR2 interacts with TNFR-associ-
ated death domain protein (TRADD), receptor-interacting protein
(RIP) [9,10] and BS69 [11]. Signals through these two domains in-
duce p100 and p105 NF-jB precursors and generate p52 and p50
subunits, respectively [12,13], indicating that LMP1 is involved in
both canonical and non-canonical activation of NF-jB pathway.
Binding of LMP1 to TRAFs and TRADD also initiates the formation
of a signaling complex that leads to activation of mitogen-acti-
vated protein kinase, p38 [14]. In addition, activation of c-Jun
N-terminal kinase (JNK) by LMP1 is mediated through CTAR1
and CTAR2 [15].
BS69, a multidomain cellular protein containing PHD, Bromo,
PWWP and MYND domains, was originally identiﬁed as an adeno-
virus E1A-binding protein that inhibits the transactivation function
of E1A [16]. Furthermore, the C-terminal MYND domain of BS69
was shown to bind to the PXLXP motif existing on E1A, the EBV-en-
coded EBNA2 and a Myc-related cellular protein MGA [17]. It has
recently been shown that BS69 interacts with EBV-encoded
LMP1, through its MYND domain and acts as a scaffold protein inlsevier B.V. All rights reserved.
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However, the involvement of BS69 in LMP1-mediated NF-jB acti-
vation is still undetermined. Here, we investigated the inﬂuence
of BS69 on LMP1-mediated NF-jB activation.
Our main ﬁnding was that BS69 could downregulate LMP1-
mediated NF-jB activation including LMP1-induced interleukin
(IL)-6 mRNA expression and IjB degradation. We further found
that BS69 decreases complex formation between LMP1 and
TRADD. Therefore, BS69 is likely to act as an endogenous negative
regulator of LMP1-mediated NF-jB activation by displacing TRADD
from LMP1.2. Materials and methods
2.1. Reagents and antibodies
Recombinant human TNF-a was kindly provided from Dai-
nippon Sumitomo Pharma (Osaka, Japan). Expression vectors
for BS69, BRAM1, TRADD and NF-jB-LUC were kindly provided
by H. Shibuya (Tokyo Medical and Dental University, Tokyo, Ja-
pan), N. Inohara (University of Michigan Medical School, Ann
Arbor, MI) and T. Fujita (Kyoto University, Kyoto, Japan) [18–
20]. Epitope-tagged STAP-2 and epitope-tagged LMP1 constructs
were described previously [19,20] The following primary anti-
bodies were obtained commercially: anti-TRADD, anti-NF-jB
p65 and anti-Myc antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-FLAG mAb (M2) and anti-HA antibody (Sigma–
Aldrich, St. Louis, MO); anti-IjB antibody, anti-phospho-JNK
(pJNK) and anti-JNK (Cell Signaling Technology, Beverly, MA);
and anti-actin mAb (Chemicon International, Temecula, CA).
An anti-LMP1 mAb (S12) was prepared as described previously
[19].
2.2. Cell culture and transfection
A human cervix carcinoma cell line (HeLa), human embryonic
kidney carcinoma cell line (293T) and human hepatoma cell line
(Hep3B) were maintained in DMEM containing 10% FCS. HeLa/
pcDNA3 and HeLa/STAP-2 transfectants were prepared as de-
scribed previously [19]. HeLa cells were transfected using jetPEI
(PolyPlus-transfection, Strasbourg, France) according to the manu-
facturer’s instructions. 293T cells were transfected using a stan-
dard calcium precipitation protocol [21].
2.3. Transfection of small-interfering RNAs (siRNAs) and luciferase
assays
The siRNAs targeting human BS69 (#1 and #2) used in this
study were as follows: BS69#1, 50-GGAUGAAGUCGGACCACA-
ATT-30; BS69#2, 50-GAAGUUAUGAAGAGUUCAATT-30. HeLa and
Hep3B cells were plated on 24-well plates at 2  104 cells/well
and incubated with an siRNA-Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) mixture at 37 C for 4 h, followed by the addition
of fresh medium containing 10% FCS. HeLa cells were further
transfected with or without NF-jB-LUC with or without LMP1
using jetPEI as described in the section above. At 24 h after trans-
fection, the cells were harvested and assayed for their luciferase
activities using a Dual-Luciferase Reporter Assay System (Prome-
ga, Madison, WI) according to the manufacturer’s instructions.
293T cells were transfected as described in the section above.
The cells were harvested at 36 h after transfection, lysed in
50 ll of Reporter Lysis Buffer (Promega) and assayed for their
luciferase and b-galactosidase activities according to the manu-
facturer’s instructions. Three or more independent experiments
were carried out for each assay.2.4. Immunoprecipitation and immunoblotting
Immunoprecipitation and Western blotting assays were per-
formed as described previously [21]. The immunoprecipitates from
cell lysates were resolved by SDS–PAGE and transferred to PVDF
membranes (PerkinElmer, Boston, MA). The membranes were then
immunoblotted with the different primary antibodies. Immunore-
active proteins were visualized using an enhanced chemilumines-
cence detection system (Millipore, Bedford, MA).
2.5. RNA isolation, RT-PCR and quantitative real-time PCR
After cell harvesting, total RNA samples were extracted using
Iso-Gen (Nippon Gene, Tokyo, Japan) and subjected to RT-PCR
using an RT-PCR High-Plus- Kit (TOYOBO, Tokyo, Japan) [19]. Prim-
ers used for RT-PCR were: BS69: 50-GGATATTGGTTGCCAGGA GA-30
(sense), 50-GTGCCCATCTCCTGTTTGTT-30 (antisense). Quantitative
real-time PCR analyses for IL-6, BS69 and control G3PDH mRNA
transcripts were carried out using Assays-on-DemandTM gene-spe-
ciﬁc ﬂuorescently-labeled TaqMan MGB probes in an ABI Prism
7000 sequence detection system (Applied Biosystems, Foster City,
CA).
2.6. Indirect immunoﬂuorescence microscopy
To analyze the subcellular localization of LMP1 and BS69 pro-
teins, FLAG-tagged LMP1 and HA-tagged BS69 were transiently
transfected into HeLa cells by Jet-PEI. Immunoﬂuorescence stain-
ings were performed as described [19]. The following primary anti-
bodies were used: mouse anti-HA and rabbit anti-FLAG antibodies.
Two secondary antibodies were used: rhodamine-conjugated anti-
mouse IgG or ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG (Chemicon). DNA was visualized with DAPI (Wako
Chemicals, Osaka, Japan) staining. Confocal laser scanning micros-
copy was performed with a LSM510 microscope (Carl Zeiss, Thorn-
wood, NY) with an Apochromat 63/1.4 oil immersion objective,
using excitation wavelengths of 543 nm (rhodamine red) and
488 nm (FITC).3. Results and discussion
3.1. BS69 negatively regulates LMP1-induced NF-jB activation
We previously showed that STAP-2 suppressed LMP1-induced
NF-jB activation and that overexpression of BS69 failed to affect
the negative effects of STAP-2 [19]. However, information that
BS69 can bind to the cytoplasmic C-terminal domain of LMP1
[10] let us investigate the individual effects of BS69 on LMP1-in-
duced NF-jB activation using transient reporter assays with NF-
jB-LUC. NF-jB-LUC activities were markedly induced by the
expression of LMP1 in HeLa and 293T cells (Fig. 1). Importantly,
the LMP1-induced NF-jB-LUC activities were signiﬁcantly re-
duced by co-expression of BS69 in a dose-dependent manner,
suggesting that BS69 negatively regulates LMP1-induced NF-jB
activation. Recently, an alternatively spliced variant of BS69,
BRAM1has also been shown to interact with the C-terminal do-
main of LMP1 and inﬂuence LMP1-mediated NF-jB activation
[22]. BRAM1 protein shares the C-terminal 186 amino acids
including a MYND domain with BS69 [18]. Thus, we examined
the effect of BRAM1 on LMP1-induced NF-jB activation in the
same situation. As shown in Fig. 1B, BRAM1 as well as BS69 de-
creased LMP1-induced NF-jB activation, and similar amounts of
both proteins were required for this suppressive effect. To ex-
clude the possibility that the suppression of NF-jB activation is
a result of promoter interference, the expression vector carrying
Fig. 1. BS69 negatively regulates LMP1-induced NF-jB activation. (A) HeLa cells in 12-well plates were transfected with HA-tagged LMP1 (10 ng) and NF-jB-LUC (100 ng)
and/or increasing amounts of HA-tagged BS69 (30, 150 or 300 ng) using jetPEI. At 48 h after transfection, the cells were harvested and assayed for their luciferase activities
using a Dual-Luciferase Reporter Assay System. An aliquot of each total cell lysate (TCL) was analyzed by immunoblotting with an anti-HA antibody. (B) 293T cells in 12-well
plates were transfected with HA-tagged LMP1 (10 ng) and NF-jB-LUC (100 ng) and/or increasing amounts of empty vector, HA-tagged BS69 or BRAM1 (150, 300 ng). At 48 h
after transfection, the cells were harvested and the luciferase activities were measured. An aliquot of each TCL was analyzed by immunoblotting with an anti-HA antibody. (C)
293T cells in 12-well plates were transfected with HA-tagged LMP1 (10 ng) and NF-jB-LUC (100 ng) and/or increasing amounts of FLAG-tagged TRAF1 (150, 300 ng). At 48 h
after transfection, the cells were harvested and the luciferase activities were measured. An aliquot of each TCL was analyzed by immunoblotting with an anti-FLAG antibody.
(D) HeLa cells in 12-well plates were transfected with HA-tagged LMP1 (10 ng) and/or increasing amounts of empty vector, HA-tagged BS69 or BRAM1 (150 or 300 ng). At
36 h after transfection, the cells were stimulated with TNF-a (10 ng/ml) for additional 8 h. The stimulated cells were harvested, and luciferase activities were measured. An
aliquot of each TCL was analyzed by immunoblotting with an anti-HA antibody. (E) 293T cells in 12-well plates were transfected with HA-tagged LMP1 (10 ng) and/or
increasing amounts of empty vector, HA-tagged BS69 or BRAM1 (150, 300 ng). At 48 h after transfection, the cells were lysed and total extracts were immunoblotted with
anti-pJNK, anti-JNK, anti-HA or anti-actin antibodies.
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NF-jB activation was analyzed in those cells. As expected, over-
expression of TRAF1 failed to inﬂuence NF-jB-LUC activity in-
duced by LMP1 (Fig. 1C). We then tested the effect of ectopic
exprerssion of BS69 or BRAM1 on NF-jB activation induced byTNF-a, which uses different signaling pathway from LMP1. As
shown in Fig. 1D, neither BRAM1 nor BS69 overexpression re-
duced TNF-a-induced NF-jB-LUC activity in HeLa cells. Therefore,
overexpression of BS69 negatively regulated LMP1-induced NF-jB
activation. BS69 is shown to act as a scaffold protein in the
1570 O. Ikeda et al. / FEBS Letters 583 (2009) 1567–1574LMP1-mediated JNK pathway [11]. We also examined the effect of
BS69 and BRAM1 on LMP1-induced JNK activation using a phos-
pho-speciﬁc anti-JNK antibody. As shown in Fig. 1E, ectopic
expression of BS69 enhanced LMP1-induced JNK activation as
previously reported [11]. However, BRAM1 expression had no ef-
fect on LMP1-induced JNK activation. Therefore, BS69 but not
BRAM1 positively regulates LMP1-mediated JNK pathway.
To further explore whether BS69 represses LMP1-induced NF-
jB activation, we used siRNAs to reduce endogenous expressionFig. 2. Reduction of endogenous BS69 enhances LMP1-induced NF-jB activation. (A) He
human BS69 (#1 and #2). The BS69 expression levels were quantiﬁed by RT and quantit
that of G3PDH mRNA as an internal control and are expressed relative to the value at tim
varied by <10%. (B) HeLa cells in 24-well plates were transfected with a control siRNA o
(3 ng) and NF-jB-LUC (100 ng) using jetPEI. At 48 h after transfection, the cells were h
experiments were carried out for each assay. *P < 0.05 **P < 0.01. An aliquot of each tota
Hep3B cells in 24-well plates were transfected with a control or BS69 siRNA (#2). The cel
jetPEI. At 48 h after transfection, the cells were harvested and the luciferase activities wer
*P < 0.01. An aliquot of each TCL was analyzed by immunoblotting with an anti-HA antib
siRNAs (#1 and #2). The cells were then transfected with HA-tagged LMP1 (1.5 lg) using
their IL-6 mRNA expression levels by RT and quantitative real-time PCR analysis. Data re
control and are expressed relative to control siRNA-treated samples without LMP1. Dat
<10%. An aliquot of each TCL was analyzed by immunoblotting with an anti-HA antibo
siRNAs (#1 and #2). The cells were then transfected with HA-tagged LMP1 (1.5 lg) us
immunoblotted with anti-IjBa, anti-HA or anti-actin antibodies.of BS69 in HeLa cells (Fig. 2). HeLa cells were transfected with spe-
ciﬁc siRNAs for BS69 (#1 and #2) or a control siRNA. Total RNA iso-
lated from the transfected cells was subjected to RT-PCR and
quantitative real-time PCR analysis, which conﬁrmed a reduction
of BS69 mRNA expression. We then determined the effects of
BS69 siRNAs on LMP1-induced NF-jB activation in HeLa cells. As
shown in Fig. 2B, siRNA-mediated reduced expression of BS69 re-
sulted in a signiﬁcant enhancement of LMP1-induced NF-jB-LUC
activities in these cells. 293T cells express adenovirus E1A, andLa cells in 24-well plates were transfected with a control siRNA or siRNAs targeting
ative real-time PCR analysis. Data represent the levels of BS69 mRNA normalized by
e zero. Data represent the means of duplicate PCR determinations, which generally
r BS69 siRNAs (#1 and #2). The cells were then transfected with HA-tagged LMP1
arvested and the luciferase activities were measured. At least three independent
l cell lysate (TCL) was analyzed by immunoblotting with an anti-HA antibody. (C)
ls were then transfected with HA-tagged LMP1 (3 ng) and NF-jB-LUC (100 ng) using
e measured. At least three independent experiments were carried out for each assay.
ody. (D) HeLa cells in 12-well plates were transfected with a control siRNA or BS69
jetPEI. At 48 h after transfection, total RNA samples were extracted and analyzed for
present the levels of IL-6 mRNA normalized by that of G3PDH mRNA as an internal
a represent the means of duplicate PCR determinations, which generally varied by
dy. (E) HeLa cells in 12-well plates were transfected with a control siRNA or BS69
ing jetPEI. At 48 h after transfection, the cells were lysed and total extracts were
O. Ikeda et al. / FEBS Letters 583 (2009) 1567–1574 1571HeLa cells are known to express human papillomavirus E7 onco-
protein that is structurally and functionally related to E1A and
may also bind BS69 [23]. Because the presence of these virus-re-
lated oncoprotein may affect the effect of BS69, we conﬁrmed di-
rect effect of BS69 siRNAs on LMP1-induced NF-jB activation in
E7 negative human hepatoma Hep3B cells. As shown in Fig. 2C, siR-
NA-mediated reduced expression of BS69 resulted in a signiﬁcant
enhancement of LMP1-induced NF-jB-LUC activities in the virus-
related oncoprotein negative cells.
NF-jB activation induces the production of inﬂammatory
cytokines, such as IL-6. To conﬁrm the regulation of LMP1-in-
duced NF-jB activation by BS69, LMP1-induced IL-6 mRNA
expression was analyzed in the BS69 siRNA-treated HeLa cells.
LMP1-induced IL-6 mRNA expression was augmented in LMP1-
transfected HeLa cells in parallel with the decrease of BS69
(Fig. 2D). To further assess the effects of BS69 on LMP1-induced
canonical NF-jB activation, we examined the effects of BS69 siR-
NA on LMP1-induced IjBa degradation. The BS69 siRNA-medi-
ated reduction of BS69 markedly enhanced LMP1-induced IjBa
degradation in HeLa cells (Fig. 2E). In addition, IL-6 mRNA
expression and IjBa degradation were slightly enhanced in the
BS69 siRNA-treated HeLa cells even in the absence of LMP1-
expression. There might be the possibility that endogenous
BS69 regulates basal NF-jB activation by interacting with potent
NF-jB activators such as TRAF6, because BS69 has been shown
to bind to TRAF6 [11]. At the present time, we do not know
the mechanisms of regulation of basal NF-jB activation by
BS69. Further detailed study will be required to clarify this issue.
Taking these results together, BS69 acts as a negative regulator
in LMP1-mediated NF-jB activation.Fig. 3. BS69 co-localizes with LMP1. (A) HeLa cells in a 12-well plate were transfected w
transfection, the cells were ﬁxed and reacted with anti-FLAG or anti-HA antibodies, and
was also stained with DAPI for the nuclei staining. These ﬁgures were merged. (B) HeLa ce
BS69 (1 lg) using jetPEI. At 48 h after transfection, the cells were ﬁxed and reacted
conjugated secondary antibody. These ﬁgures were merged. The same slide was also stai
with LMP1. (C) HeLa cells in a 12-well plate were transfected with HA-tagged BS69 (1 lg
NF-jB p65 and anti-HA antibodies, and visualized with FITC- or rhodamine-conjugated se
DAPI for the nuclei staining.3.2. Intracellular localization of BS69, LMP1, and NF-jB
We examined cellular co-localization of BS69 and LMP1 in vivo
using confocal microscopy. HeLa cells were transfected with FLAG-
tagged LMP1 and HA-tagged BS69 constructs. BS69 was mainly
localized in the nucleus (Fig. 3A). However, when co-expressed
with LMP1, BS69 protein was in part concentrated in punctate
vesicular-like and perinuclear structures where LMP1 was also
mainly localized, demonstrating that LMP1 co-localized with
BS69 in vivo (Fig. 3B). We further examined whether expression
of BS69 has any effect of cellular localization of NF-jB p65
in vivo. As shown in Fig. 3C, even in the presence of BS69, NF-jB
p65 protein was mainly localized in the cytoplasm. Co-localization
of BS69 with NF-jB p65 and a signiﬁcant nuclear translocation of
NF-jB p65 were not observed, suggesting that BS69 has no direct
effect on NF-jB p65 in the regulation of NF-jB signaling.
3.3. BS69 regulates LMP1-induced NF-jB activation by displacing
TRADD from LMP1
In a previous study, BS69 has been demonstrated to interact
with the CTAR2 domain of LMP1 and activate the JNK pathway
by interacting with TRAF6 [11]. To further examine the molecular
mechanisms of BS69-mediated suppression of NF-jB activation,
we tested whether BS69 associates with other downstream mol-
ecules through the CTAR2 domain for LMP1-mediated NF-jB acti-
vation such as TRADD and STAP-2. We have demonstrated that
siRNA-mediated reduction of TRADD results in a signiﬁcant de-
crease of LMP1-mediated NF-jB-LUC activities in HeLa cells,
whereas siRNA-mediated reduction of STAP-2 revealed aith FLAG-tagged LMP1 (1 lg) or HA-tagged BS69 (1 lg) using jetPEI. At 48 h after
visualized with FITC- or rhodamine-conjugated secondary antibody. The same slide
lls in a 12-well plate were transfected with FLAG-tagged LMP1 (1 lg) and HA-tagged
with anti-FLAG and anti-HA antibodies, and visualized with FITC- or rhodamine-
ned with DAPI for the nuclei staining. The arrowheads show co-localization of BS69
) using jetPEI. At 48 h after transfection, the cells were ﬁxed and reacted with anti-
condary antibody. These ﬁgures were merged. The same slide was also stained with
Fig. 4. BS69 displaces TRADD from LMP1. (A) 293T cells (1  107) were transfected with Myc-tagged STAP-2 (10 lg) with or without HA-tagged BS69 (10 lg). At 48 h after
transfection, the cells were lysed, immunoprecipitated with an anti-HA antibody and immunoblotted with an anti-Myc or anti-HA antibody. An aliquot of each total cell
lysate (TCL) was immunoblotted with the anti-Myc antibody. (B) 293T cells (1  107) were transfected with Myc-tagged STAP-2 (10 lg) with or without HA-tagged BRAM1
(10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with an anti-HA antibody and immunoblotted with an anti-Myc or anti-HA antibody. An aliquot
of each TCL was immunoblotted with the anti-Myc antibody. (C) 293T cells (1  107) were transfected with HA-tagged TRADD (10 lg) with or without FLAG-tagged BS69
(10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with an anti-FLAG antibody and immunoblotted with an anti-HA or anti-FLAG antibody. An
aliquot of each TCL was immunoblotted with the anti-HA antibody. (D) 293T cells (1  107) were transfected with HA-tagged TRADD (10 lg) with or without HA-tagged
BRAM1 (10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with an anti-TRADD antibody and immunoblotted with an anti-HA antibody. An aliquot
of each TCL was immunoblotted with the anti-HA antibody. (E) 293T cells (1  107) were transfected with FLAG-tagged LMP1 (10 lg) or HA-tagged TRADD (10 lg) and/or HA-
tagged BS69 (10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with anti-FLAG antibody and immunoblotted with an anti-HA or anti-FLAG
antibody. An aliquot of each TCL was immunoblotted with the anti-HA antibody. (F) 293T cells (1  107) were transfected with FLAG-tagged LMP1 (10 lg) or HA-tagged
TRADD (10 lg) and/or HA-tagged BRAM1 (10 lg). At 48 h after transfection, the cells were lysed, immunoprecipitated with anti-FLAG antibody and immunoblotted with an
anti-HA or anti-FLAG antibody. An aliquot of each TCL was immunoblotted with the anti-HA antibody.
1572 O. Ikeda et al. / FEBS Letters 583 (2009) 1567–1574signiﬁcant enhancement of NF-jB activation in HeLa cells [19]. To
delineate the molecular interactions between BS69 and these
molecules, we ﬁrst examined whether BS69 directly interacts
with TRADD or STAP-2 in vivo. 293T cells were transfected with
either HA-tagged TRADD or Myc-tagged STAP-2 together with
HA-tagged BS69. Western blot analysis of the associated proteins
with an anti-HA or anti-Myc antibody revealed that BS69 did not
interact with either STAP-2 or TRADD (Fig. 4A and C). BRAM1 also
failed to interact with STAP-2 or TRADD (Fig. 4B and D). We pre-
viously demonstrated that STAP-2 displaces TRADD from LMP1
and inhibits LMP1-mediated NF-jB activation. We then examined
the effects of BS69 or BRAM1on the interactions between LMP1
and TRADD. Interestingly, TRADD failed to bind to LMP1 in the
presence of BS69 or BRAM1 (Fig. 4E and F), indicating that BS69
and BRAM1 inhibit physical interactions between LMP1 and
TRADD. These results suggest that BS69 decreases the formation
of LMP1/TRADD complexes through the C-terminal region encod-
ing BRAM1.
3.4. Concluding remarks
We here demonstrate that BS69 negatively regulates LMP1-
mediated NF-jB activation by displacing TRADD from LMP1. Pre-
vious studies demonstrated that BS69 acts as a transcription
repressor in association with a variety of transcription factorssuch as c-Myb, B-Myb, Ets2 and MGA [24–27]. BS69 has also been
shown to repress transcription by recruiting N-CoR [28]. Further-
more, BS69 has also been shown to associate with mitotic chro-
mosomes and interacts with Brg1 (the catalytic subunit of the
mammalian SWI/SNF complex), indicating another role of BS69
in chromatin remodeling [29]. BS69 was originally identiﬁed as
an adenovirus E1A-binding protein that inhibits the transactiva-
tion function of E1A [16] by interacting with the PXLXP motif
present in E1A. These functions may be coincident with the fact
that BS69 negatively regulates EBV LMP1-mediated NF-jB and
JNK signaling pathways.
Interestingly, BRAM1, an alternatively spliced form of BS69, re-
tains the full MYND domain and is shown to interact with the
BMP receptor 1A. Recently, BRAM1 has been shown to associate
with the C-terminal domain of LMP1 through its MYND domain.
Interactions between LMP1 and BRAM1 result in the inhibition
of LMP1-mediated NF-jB activation but not JNK activation.
BRAM1 inﬂuences LMP1-mediated and TNF-a-induced NF-jB
activation by targeting the posttranslational modiﬁcations of
IjB. In the present study, we show another possible mechanism
that BS69 as well as BRAM1 can displace TRADD from LMP1
and inhibit LMP1-mediated NF-jB activation. We also tested
whether BS69 and BRAM1 bind to LMP1 ID mutant, a site-speciﬁc
mutant of LMP1 with a defective TRADD binding site by a substi-
tution of ID for YYD in the last three amino acid residues of the
Fig. 5. Scheme of functional proposal of BS69 in the suppression of LMP1-induced
NF-jB activation. LMP1 consists N-terminal tail, six transmembrane domain and a
long cytoplasmic C-terminal domain which contains two NF-jB activating domain,
CTAR1and CTAR2. BS69 directly interacts with LMP1 and suppresses LMP1-induced
NF-jB activation through CTAR2. BS69 and its alternative spliced form, BRAM1
regulate CTAR2-mediated canonical NF-jB activation by displacing TRADD from
LMP1. LMP1-induced JNK activation is mediated by BS69 and TRAF6. BS69 also
interacts with EBV-encoded latency nuclear protein EBNA2.
O. Ikeda et al. / FEBS Letters 583 (2009) 1567–1574 1573C-terminal region of LMP1 protein (positions 384–386) [10]. Both
BS69 and BRAM1, but not TRADD interacted with LMP1 ID mu-
tant protein (data not shown), suggesting that the BS69/BRAM1
binding site may be close but not identical to the TRADD binding
site. The TRADD binding to LMP1 might be competed by BS69/
BRAM1 due to their steric effects. More detailed analysis of
molecular interactions between LMP1, TRADD and BS69/BRAM1
will be required.
BS69 has also been demonstrated to interact with EBV-encoded
latency protein EBNA2 [30]. EBNA2 is a nuclear transcriptional
activator that is essential for EBV-induced cellular transformation.
BS69 may also regulate EBNA2-mediated transcriptional activation
in the nucleus of the EBV-infected cells. Interestingly, we previ-
ously showed that LMP1 expression upregulated STAP-2 expres-
sion, suggesting that STAP-2 plays a role in the defense of host
cells against EBV infection. However, we could not observe any
alteration of BS69 mRNA expression by LMP1 expression (data
not shown). This ﬁnding indicates that BS69 is constitutively ex-
pressed and functions in the defense of host cells against EBV
infection by interfering with dysregulated transcriptional activa-
tion mediated by LMP1 or EBNA2. We have also provided evidence
that BS69 can inhibit EBV LMP1-mediated NF-jB activation
through a direct modulation of interactions with TRADD, and our
proposed mechanisms are now illustrated in Fig. 5. Our data sug-
gest the possibility that BS69 may be a novel candidate for anti-vir-
al therapy to regulate EBV LMP1-induced NF-jB and JNK
pathways.
Acknowledgements
We thank S. Nakazato and N. Kodama for technical assistance.
This study was supported in part by Grant-in-Aid for scientiﬁc re-
search from Ministry of Education, Culture, Sports, Science and
Technology of Japan.References
[1] Kieff, E. (1996) Epstein-Barr virus and its replication in: Fields Virology (Field,
D.M., Knipe, D.M. and Howley, P.M., Eds.), vol. 2, 3rd ed, pp. 2343–2396,
Springer, NY.
[2] Liebowitz, D., Wang, D. and Kieff, E. (1989) Orientation and patching of the
latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58,
233–237.
[3] Li, H.P. and Chang, Y.S. (2003) Epstein–Barr virus latent membrane protein 1:
structure and functions. J. Biomed. Sci. 10, 490–504.
[4] Huen, D.S., Henderson, S.A., Croom-Carter, D. and Rowe, M. (1995) The
Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of
NF-kappa B and cell surface phenotype via two effector regions in its carboxy-
terminal cytoplasmic domain. Oncogene 10, 549–560.
[5] Brodeur, S.R., Cheng, G., Baltimore, D. and Thorley-Lawson, D.A. (1997)
Localization of the major NF-kappaB-activating site and the sole TRAF3
binding site of LMP-1 deﬁnes two distinct signaling motifs. J. Biol. Chem. 272,
19777–19784.
[6] Devergne, O.E., Hatzivassiliou, K.M., Izumi, K.M., Kaye, K.M., Kleijnen, K.F.,
Kieff, E. and Mosialos, G. (1996) Association of TRAF1, TRAF2, and TRAF3 with
an Epstein–Barr virus LMP1 domain important for B-lymphocyte
transformation: role in NF-kappaB activation. Mol. Cell Biol. 16, 7098–7108.
[7] Kaye, K.M., Devergne, O., Harada, J.N., Izumi, K.M., Yalamanchili, R., Kieff, E. and
Mosialos, G. (1996) Tumor necrosis factor receptor associated factor 2 is a
mediator of NF-kappa B activation by latent infection membrane protein 1, the
Epstein–Barr virus transforming protein. Proc. Natl. Acad. Sci. USA 93, 11085–
11090.
[8] Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. and
Kieff, E. (1995) The Epstein–Barr virus transforming protein LMP1 engages
signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389–
399.
[9] Izumi, K.M. and Kieff, E. (1997) The Epstein–Barr virus oncogene product
latent membrane protein 1 engages the tumor necrosis factor receptor-
associated death domain protein to mediate B lymphocyte growth
transformation and activate NF-kappaB. Proc. Natl. Acad. Sci. USA 94,
12592–12597.
[10] Izumi, K.M., Cahir-McFarland, E.D., Ting, A.T., Riley, E.A., Seed, B. and Kieff, E.
(1999) The Epstein–Barr virus oncoprotein latent membrane protein 1
engages the tumor necrosis factor receptor-associated proteins TRADD and
receptor-interacting protein (RIP) but does not induce apoptosis or require RIP
for NF-kappaB activation. Mol. Cell Biol. 19, 5759–5767.
[11] Wan, J., Zhang, W., Wu, L., Bai, T., Zhang, M., Lo, K.W., Chui, Y.L., Cui, Y., Tao, Q.,
Yamamoto, M., Akira, S. and Wu, Z. (2006) BS69, a speciﬁc adaptor in the
latent membrane protein 1-mediated c-Jun N-terminal kinase pathway. Mol.
Cell Biol. 26, 448–456.
[12] Laherty, C.D., Hu, H.M., Opipari, A.W., Wang, F. and Dixit, V.M. (1992) The
Epstein–Barr virus LMP1 gene product induces A20 zinc ﬁnger protein
expression by activating nuclear factor kappa B. J. Biol. Chem. 267, 24157–
24160.
[13] Luftig, M., Yasui, T., Soni, V., Kang, M.S., Jacobson, N., Cahir-McFarland, E., Seed,
B. and Kieff, E. (2004) Epstein–Barr virus latent infection membrane protein 1
TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB
activation. Proc. Natl. Acad. Sci. USA 101, 141–146.
[14] Eliopoulos, A.G., Gallagher, N.J., Blake, S.M., Dawson, C.W. and Young, L.S.
(1999) Activation of the p38 mitogen-activated protein kinase pathway by
Epstein–Barr virus-encoded latent membrane protein 1 coregulates
interleukin-6 and interleukin-8 production. J. Biol. Chem. 274, 16085–16096.
[15] Eliopoulos, A.G. and Young, L.S. (1998) Activation of the cJun N-terminal
kinase (JNK) pathway by the Epstein–Barr virus-encoded latent membrane
protein 1 (LMP1). Oncogene 16, 1731–1742.
[16] Hateboer, G., Gennissen, A., Ramos, Y.F., Kerkhoven, R.M., Sonntag-Buck, V.,
Stunnenberg, H.G. and Bernards, R. (1995) BS69, a novel adenovirus E1A-
associated protein that inhibits E1A transactivation. EMBO J. 14, 3159–
3169.
[17] Ansieau, S. and Leutz, A. (2002) The conserved Mynd domain of BS69 binds
cellular and oncoviral proteins through a common PXLXP motif. J. Biol. Chem.
277, 4906–4910.
[18] Kurozumi, K., Nishita, M., Yamaguchi, K., Fujita, T., Ueno, N. and Shibuya, H.
(1998) BRAM1, a BMP receptor-associated molecule involved in BMP
signaling. Genes Cells 3, 257–264.
[19] Ikeda, O., Sekine, Y., Yasui, T., Oritani, K., Sugiyma, K., Muromoto, R.,
Ohbayashi, N., Yoshimura, A. and Matsuda, T. (2008) STAP-2 negatively
regulates both canonical and non-canonical NF-kappaB activation induced by
Epstein–Barr virus-derived LMP1. Mol. Cell Biol. 28, 5027–5042.
[20] Sekine, Y., Yumioka, T., Yamamoto, R., Muromoto, R., Imoto, S., Sugiyma, K.,
Oritani, K., Shimoda, K., Minoguchi, M., Akira, S., Yoshimura, A. and Matsuda, T.
(2006) Modulation of TLR4 signaling by a novel adaptor protein signal-
transducing adaptor protein-2 in macrophages. J. Immunol. 176, 380–389.
[21] Matsuda, T., Yamamoto, T., Muraguchi, A. and Saatcioglu, F. (2001) Cross-talk
between TGF-eta and estrogen receptor signaling through Smad3. J. Biol.
Chem. 276, 42907–42914.
[22] Chung, P.J., Chang, Y.S., Liang, C.L. and Meng, C.L. (2002) Negative regulation of
Epstein–Barr virus latent membrane protein 1-mediated functions by the
bone morphogenetic protein receptor IA-binding protein, BRAM1. J. Biol.
Chem. 277, 39850–39857.
1574 O. Ikeda et al. / FEBS Letters 583 (2009) 1567–1574[23] Phelps, W.C., Yee, C.L., Münger, K. and Howley, P.M. (1988) The human
papillomavirus type 16 E7 gene encodes transactivation and transformation
functions similar to those of adenovirus E1A. Cell 53, 539–547.
[24] Ladendorff, N.E., Wu, S. and Lipsick, J.S. (2001) BS69, an adenovirus E1A-
associated protein, inhibits the transcriptional activity of c-Myb. Oncogene 20,
125–132.
[25] Masselink, H., Vastenhouw, N. and Bernards, R. (2001) B-myb rescues ras-
induced premature senescence, which requires its transactivation domain.
Cancer Lett. 171, 87–101.
[26] Wei, G., Schaffner, A.E., Baker, K.M., Mansky, K.C. and Ostrowski, M.C. (2003)
Ets-2 interacts with co-repressor BS69 to repress target gene expression.
Anticancer Res. 23, 2173–2178.[27] Ekblad, C.M., Chavali, G.B., Basu, B.P., Freund, S.M., Veprintsev, D., Hughes-
Davies, L., Kouzarides, T., Doherty, A.J. and Itzhaki, L.S. (2005) Binding of EMSY
to HP1beta: implications for recruitment of HP1beta and BS69. EMBO Rep. 6,
675–680.
[28] Masselink, H. and Bernards, R. (2000) The adenovirus E1A binding protein
BS69 is a corepressor of transcription through recruitment of N-CoR.
Oncogene 19, 1538–1546.
[29] Velasco, G., Grkovic, S. and Ansieau, S. (2006) New insights into BS69
functions. J. Biol. Chem. 281, 16546–16550.
[30] Ansieau, S. and Leutz, A. (2002) The conserved Mynd domain of BS69 binds
cellular and oncoviral proteins through a common PXLXP motif. J. Biol. Chem.
277, 4906–4910.
